Categories
Change Password!
Reset Password!
Patent ductus arteriosus (PDA) remains a prevalent cardiac condition in neonates.
In premature infants, paracetamol is more beneficial than ibuprofen in closing patent ductus arteriosus, with its higher success rate supporting its potential as the preferable first-line intervention.
Patent ductus arteriosus (PDA) remains a prevalent cardiac condition in neonates. This randomized controlled trial explored whether paracetamol or ibuprofen offers superior efficacy in promoting PDA closure, aiming to guide clinical decision-making.
Neonates were eligible if they were 48–96 hours old, had a gestational age of 30–37 weeks, and a birth weight of ≥1250 g. Inclusion required clinical signs along with echocardiographic evidence of PDA, marked by at least one of the following: poor cardiac function, end-diastolic aortic flow reversal, duct size >2 mm, or left atrium-to-aorta ratio >1.4. A total of 256 neonates diagnosed with PDA were randomized to get either oral paracetamol (Group A) or oral ibuprofen (Group B). Treatment outcomes were assessed at the end of the therapy period.
The mean neonatal age at enrollment was 71.79 ± 13.10 hours in Group A and 73.40 ± 11.81 hours in Group B. PDA closure was observed in 107 (83.6%) neonates in the paracetamol group compared to 90 (70.3%) in the ibuprofen group, indicating a statistically significant difference (P = 0.011).
Paracetamol illustrated greater potency than ibuprofen in achieving PDA closure, suggesting its potential as the preferred therapeutic option in preterm neonates.
Molecular and Cellular Pediatrics
Comparison of the Effectiveness of Paracetamol and Ibuprofen in the Management of Patent Ductus Arteriosus in Preterm Neonates: A Randomized Controlled Trial
S. Mohsin Ali Shah et al.
Comments (0)